Company News: FDA, Genentech and MannKind

Share this article:
The FDA approved Actemra, a novel biologic from Roche Holdings's Genentech unit, for treating rheumatoid arthritis in patients who have failed other therapies. The drug will compete with Johnson & Johnson's Remicade and Abbott Labs' Humira, both of which are designed to inhibit tumor necrosis factor. Actemra is designed to block interleukin-6.

MannKind said the FDA will not be able to review an NDA for its inhaled-insulin therapy by the scheduled action date of Jan. 16, as the agency has not finished inspecting the manufacturing facilities of MannKind's third party insulin supplier. The agency did not ask for any new trials or other action prior to making its decision on the device, although it still could, and MannKind is still awaiting a new PDUFA date. FDA also accepted the trade name Afrezza for the product, which was formerly known as Afresa.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters